LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 997

Search options

  1. Book: BRAF targets in melanoma

    Sullivan, Ryan J.

    biological mechanisms, resistance, and drug discovery

    (Cancer drug discovery and development ; 82)

    2015  

    Author's details Ryan J. Sullivan ed
    Series title Cancer drug discovery and development ; 82
    Collection
    Language English
    Size VIII, 204 S. : Ill., graph. Darst.
    Publisher Humana Press
    Publishing place New York u.a.
    Publishing country United States
    Document type Book
    HBZ-ID HT018536763
    ISBN 978-1-4939-2142-3 ; 9781493921430 ; 1-4939-2142-8 ; 1493921436
    Database Catalogue ZB MED Medicine, Health

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Shelf markLoan statusLocation
    2015 A 593 available for loan (reading room) Lesesaal EG

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: To Inhibit or Not to Inhibit MEK With BRAF Inhibitors: Is That the Question?

    Sullivan, Ryan J

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

    2023  Volume 41, Issue 29, Page(s) 4613–4615

    Language English
    Publishing date 2023-08-17
    Publishing country United States
    Document type Editorial
    ZDB-ID 604914-x
    ISSN 1527-7755 ; 0732-183X
    ISSN (online) 1527-7755
    ISSN 0732-183X
    DOI 10.1200/JCO.23.01380
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1847: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 650: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article: The role of triple therapy in BRAF-positive melanoma.

    Sullivan, Ryan J

    Clinical advances in hematology & oncology : H&O

    2022  Volume 20, Issue 6, Page(s) 359–361

    MeSH term(s) Humans ; Melanoma/drug therapy ; Melanoma/genetics ; Mutation ; Proto-Oncogene Proteins B-raf/genetics ; Skin Neoplasms/drug therapy ; Skin Neoplasms/genetics
    Chemical Substances BRAF protein, human (EC 2.7.11.1) ; Proto-Oncogene Proteins B-raf (EC 2.7.11.1)
    Language English
    Publishing date 2022-06-21
    Publishing country United States
    Document type Interview
    ZDB-ID 2271951-9
    ISSN 1543-0790
    ISSN 1543-0790
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6505: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: What Is the Timing and Role of Targeted Therapy in Metastatic Melanoma?

    Hadfield, Matthew J / Sullivan, Ryan J

    Cancer journal (Sudbury, Mass.)

    2024  Volume 30, Issue 2, Page(s) 84–91

    Abstract: Abstract: Melanoma is the most lethal cutaneous malignancy worldwide. The last 15 years have ushered in several regulatory approvals that have dramatically altered the landscape of treatment options for patients with melanoma. Many patients with ... ...

    Abstract Abstract: Melanoma is the most lethal cutaneous malignancy worldwide. The last 15 years have ushered in several regulatory approvals that have dramatically altered the landscape of treatment options for patients with melanoma. Many patients with melanoma harbor activating mutations in the BRAF proto-oncogene, a key component of the mitogen-activated protein kinase (MAPK) intracellular signaling pathway. Therapies targeting BRAF have led to remarkable improvements in both response rates and survival in patients with metastatic disease. In parallel with these developments in MAPK-targeted therapy has been the clinical development of immune checkpoint inhibitors, which also have improved response rates and survival in patients with metastatic disease including randomized trials compared with MAPK-targeted therapy in patients with advanced, BRAF-mutant melanoma. Immune checkpoint inhibitors have become the preferred first-line standard-of-care treatment for patients with newly diagnosed metastatic disease in patients irrespective of BRAF mutational status. Given these developments, it is now less clear how to optimize the use of MAPK-targeted therapy regarding treatment setting and in sequence with immune checkpoint inhibitor.
    MeSH term(s) Humans ; Melanoma/drug therapy ; Melanoma/genetics ; Immune Checkpoint Inhibitors/therapeutic use ; Proto-Oncogene Proteins B-raf/genetics ; Proto-Oncogene Proteins B-raf/metabolism ; Protein Kinase Inhibitors/adverse effects ; Skin Neoplasms/drug therapy ; Skin Neoplasms/genetics ; Skin Neoplasms/pathology ; Mutation ; Molecular Targeted Therapy
    Chemical Substances Immune Checkpoint Inhibitors ; Proto-Oncogene Proteins B-raf (EC 2.7.11.1) ; Protein Kinase Inhibitors
    Language English
    Publishing date 2024-03-26
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2018400-1
    ISSN 1540-336X ; 1528-9117 ; 1081-4442
    ISSN (online) 1540-336X
    ISSN 1528-9117 ; 1081-4442
    DOI 10.1097/PPO.0000000000000712
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4470: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 163: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: What, if Any, Role Is There for BRAF-Targeted Therapy in

    Sullivan, Ryan J

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology

    2022  Volume 40, Issue 36, Page(s) 4161–4165

    MeSH term(s) Humans ; Proto-Oncogene Proteins B-raf/genetics ; Melanoma/drug therapy ; Melanoma/genetics ; Molecular Targeted Therapy ; Mutation ; Skin Neoplasms/drug therapy ; Skin Neoplasms/genetics ; Protein Kinase Inhibitors/therapeutic use
    Chemical Substances Proto-Oncogene Proteins B-raf (EC 2.7.11.1) ; Protein Kinase Inhibitors ; BRAF protein, human (EC 2.7.11.1)
    Language English
    Publishing date 2022-07-21
    Publishing country United States
    Document type Editorial ; Research Support, N.I.H., Extramural ; Comment
    ZDB-ID 604914-x
    ISSN 1527-7755 ; 0732-183X
    ISSN (online) 1527-7755
    ISSN 0732-183X
    DOI 10.1200/JCO.22.01066
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1847: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 650: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: For Whom the Bell Tolls? A Toll-Like Receptor 9 Agonist's Journey from Vaccine Adjuvant to Promising Agent in Anti-PD-1-Resistant Melanoma.

    Sullivan, Ryan J

    Cancer discovery

    2022  Volume 11, Issue 12, Page(s) 2960

    Abstract: Summary: Developing effective therapies in anti-PD-1-resistant melanoma is a key unmet need. The combination of pembrolizumab with the intralesional TLR9 agonist vidutolimod showed promise in this patient population with correlative analysis suggesting ... ...

    Abstract Summary: Developing effective therapies in anti-PD-1-resistant melanoma is a key unmet need. The combination of pembrolizumab with the intralesional TLR9 agonist vidutolimod showed promise in this patient population with correlative analysis suggesting that patients with a "cold" tumor immune microenvironment may be the best patients to study further. See related article by Ribas et al., p. 2998.
    MeSH term(s) Adjuvants, Vaccine ; Humans ; Melanoma/drug therapy ; Melanoma/immunology ; Toll-Like Receptor 9 ; Tumor Microenvironment
    Chemical Substances Adjuvants, Vaccine ; Toll-Like Receptor 9
    Language English
    Publishing date 2022-06-07
    Publishing country United States
    Document type Editorial ; Comment
    ZDB-ID 2625242-9
    ISSN 2159-8290 ; 2159-8274
    ISSN (online) 2159-8290
    ISSN 2159-8274
    DOI 10.1158/2159-8290.CD-21-1226
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6916: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: Immunotherapy in Melanoma: Recent Advancements and Future Directions.

    Mooradian, Meghan J / Sullivan, Ryan J

    Cancers

    2023  Volume 15, Issue 16

    Abstract: Immune checkpoint inhibition has fundamentally altered the treatment paradigm of resectable and unresectable melanoma, resulting in dramatic improvements in patient outcomes. With these advances, the five-year overall survival in patients with newly ... ...

    Abstract Immune checkpoint inhibition has fundamentally altered the treatment paradigm of resectable and unresectable melanoma, resulting in dramatic improvements in patient outcomes. With these advances, the five-year overall survival in patients with newly diagnosed unresectable disease has eclipsed 50%. Ongoing research is focused on improving outcomes further, with a considerable emphasis on preventing de novo and acquired resistance and personalizing therapeutic options. Here, we review the ongoing advancements in the treatment of malignant melanoma, focusing on novel combination strategies that aim to build upon the successes of the last decade.
    Language English
    Publishing date 2023-08-19
    Publishing country Switzerland
    Document type Journal Article ; Review
    ZDB-ID 2527080-1
    ISSN 2072-6694
    ISSN 2072-6694
    DOI 10.3390/cancers15164176
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: The case for adjuvant BRAF-targeted therapy versus adjuvant anti-PD-1 therapy for patients with resected, high-risk melanoma.

    Mooradian, Meghan J / Sullivan, Ryan J

    Cancer

    2023  Volume 129, Issue 14, Page(s) 2117–2121

    Abstract: The development of highly effective BRAF-targeted therapy and immune checkpoint inhibition for patients with advanced metastatic melanoma has transformed the treatment of this disease. More recently, these advances have moved into the resected, high-risk ...

    Abstract The development of highly effective BRAF-targeted therapy and immune checkpoint inhibition for patients with advanced metastatic melanoma has transformed the treatment of this disease. More recently, these advances have moved into the resected, high-risk stage II and III settings. For patients with resected, BRAF-mutant stage III melanoma, there are no head-to-head data to support the use of BRAF-targeted therapy (specifically the combination of dabrafenib and trametinib) with either single-agent nivolumab or pembrolizumab. Because the relapse-free and distant metastasis-free survivals are similar in a cross-trial comparison, it is not clear what the best option for these patients is. In this piece, the authors argue on behalf of and against both approaches. PLAIN LANGUAGE SUMMARY: Two types of therapy exist for patients diagnosed with melanoma who have completed surgery and remain at high risk for tumor recurrence: (1) drugs that target the BRAF mutation (found in ∼50% of patients) and (2) immunotherapy. There are no data showing that either approach is better than the other, so the choice of which therapy is best for an individual patient can be challenging. In this article, we make arguments for and against each option.
    MeSH term(s) Humans ; Proto-Oncogene Proteins B-raf/genetics ; Neoplasm Recurrence, Local ; Adjuvants, Immunologic ; Combined Modality Therapy ; Melanoma/drug therapy ; Melanoma/genetics ; Melanoma/surgery
    Chemical Substances Proto-Oncogene Proteins B-raf (EC 2.7.11.1) ; Adjuvants, Immunologic ; BRAF protein, human (EC 2.7.11.1)
    Language English
    Publishing date 2023-05-15
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1429-1
    ISSN 1097-0142 ; 0008-543X ; 1934-662X
    ISSN (online) 1097-0142
    ISSN 0008-543X ; 1934-662X
    DOI 10.1002/cncr.34806
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.146: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Back to the Future: Rethinking and Retooling IL2 in the Immune Checkpoint Inhibitor Era.

    Sullivan, Ryan J

    Cancer discovery

    2019  Volume 9, Issue 6, Page(s) 694–695

    Abstract: IL2 is a type I cytokine that is associated, when given at high doses intravenously, with durable regressionin a subset of patients with metastatic melanoma and renal cell carcinoma, yet high toxicity limits its use. NKTR-214 is a novel pegylated IL2 ... ...

    Abstract IL2 is a type I cytokine that is associated, when given at high doses intravenously, with durable regressionin a subset of patients with metastatic melanoma and renal cell carcinoma, yet high toxicity limits its use. NKTR-214 is a novel pegylated IL2 with minor clinical activity as a single agent, but a favorable toxicity profile and compelling pharmacodynamic effects that predict utility in combination with immune checkpoint inhibition.
    MeSH term(s) Biomarkers ; Humans ; Interleukin-2/analogs & derivatives ; Kidney Neoplasms ; Polyethylene Glycols
    Chemical Substances Biomarkers ; Interleukin-2 ; Polyethylene Glycols (3WJQ0SDW1A) ; bempegaldesleukin (BNO1JG5MZC)
    Language English
    Publishing date 2019-06-04
    Publishing country United States
    Document type Journal Article ; Comment
    ZDB-ID 2625242-9
    ISSN 2159-8290 ; 2159-8274
    ISSN (online) 2159-8290
    ISSN 2159-8274
    DOI 10.1158/2159-8290.CD-19-0412
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6916: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article: The future of combination treatment with checkpoint inhibitors in melanoma.

    Sullivan, Ryan J

    Clinical advances in hematology & oncology : H&O

    2019  Volume 17, Issue 2, Page(s) 96–99

    MeSH term(s) Antineoplastic Agents/administration & dosage ; Antineoplastic Agents/adverse effects ; Antineoplastic Agents/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Biomarkers, Tumor/antagonists & inhibitors ; Clinical Decision-Making ; Disease Management ; Drug Resistance, Neoplasm ; Humans ; Melanoma/diagnosis ; Melanoma/drug therapy ; Melanoma/immunology ; Melanoma/metabolism ; Molecular Targeted Therapy/adverse effects ; Molecular Targeted Therapy/methods ; Neoplasm Metastasis ; Neoplasm Staging ; Retreatment ; Treatment Outcome
    Chemical Substances Antineoplastic Agents ; Biomarkers, Tumor
    Language English
    Publishing date 2019-03-07
    Publishing country United States
    Document type Interview
    ZDB-ID 2271951-9
    ISSN 1543-0790
    ISSN 1543-0790
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6505: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top